The National Institute of Diabetes and Digestive and Kidney Diseases will fund the university’s work to examine tissue-specific metabolic reprogramming in diabetes complications.
The university’s team of researchers specifically proposes that diabetes disrupts basic metabolic pathways in complication-prone tissues and that understanding these altered pathways will provide new targets for drug therapies that could prevent or treat diabetes complications, including diabetes-related blindness, nerve damage and kidney failure.
Related Articles on University of Michigan Health System:
University of Michigan Health Partners With Great Lakes Health Information Exchange
University of Michigan Health Pushes Back Opening of Women’s, Children’s Hospitals
U Michigan Nurses, Leadership Battle Over Contract Negotiations
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
